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Introduction {#sec1}
============

A critical aim of precision medicine is to match drugs with genomic determinants of response. Identifying tumor molecular features that affect response to specific drug treatments is especially challenging because of the typically encountered diversity of patient experiences, incomplete knowledge of the multiple molecular determinants of response and resistance factors downstream of the primary drug targets, and tumor heterogeneity. In this setting, the relative homogeneity of cell lines is advantageous, making them model systems for resolving and establishing cellular intrinsic drug response mechanisms. These features motivated the development of cancer cell line pharmacogenomic databases.

Building on the NCI-60 paradigm ([@bib1], [@bib33], [@bib34], [@bib36], [@bib44]), pharmacogenomic data portals such as the Genomics of Drug Sensitivity in Cancer (GDSC) ([@bib10], [@bib14]), the Cancer Cell Line Encyclopedia (CCLE) ([@bib4], [@bib8]), and the Cancer Therapeutics Response Portal (CTRP) ([@bib32]) have expanded to span ∼1,400 cancer cell lines. Each database provides a readily available resource for translational research, and proposals have been advanced to further enrich them to over 10,000 cancer cell lines for better coverage of tumor type diversity ([@bib5]). The NCI-60 dataset includes drug activity data for over 21,000 compounds, together with a wide range of molecular profiling data (gene expression, mutations, copy number, methylation, and protein expression). The GDSC and CCLE collections focus on drug activity data for clinically relevant drugs over larger cell line sets, together with an array of molecular profiling data that match the NCI-60 and clinical genomic analyses. The CTRP provides independent drug activity data for nearly 500 compounds over cell lines spanning most of the CCLE and GDSC collections. Each source-specific portal allows deep exploration of its associated datasets, but does not allow immediate cross-database analyses. Yet, substantial overlaps in both cell lines and drugs have the potential to empower integrative analyses, building on the complementarity of the cancer cell line datasets. However, data complexity and mundane (but significant) sources of friction, such as differences in entity naming (cell lines, drugs) and data preparation, have until now made working across databases challenging, even for those with informatics training.

To enable integrative analyses within and across data sources, we are introducing CellMinerCDB ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0015}), a web application allowing immediate, interactive exploration of the richest cancer cell line genomic and pharmacogenomic databases ([Figure 1](#fig1){ref-type="fig"}). In CellMinerCDB, named entities are transparently matched across sources, allowing cell line molecular features and drug responses to be readily compared using bivariate scatterplots and correlation analyses. Multivariate models of drug response or any genomic cell line attribute can also be assessed. Analyses can be restricted to tissues of origin, with cell lines across all sources mapped to a uniform tissue type hierarchy. Gene pathway annotations allow assessment and filtering of analysis results. CellMinerCDB is built using the publicly available rcellminer R/Bioconductor package, which provides analyses and a standard data representation format ([@bib21]). The latter also allows CellMinerCDB to be readily updated to include additional data. Although the rcellminer package ([@bib21]) is available for bioinformaticists, it requires knowledge of the R programming language to install, configure, and conduct analyses. CellMinerCDB, by contrast, is accessible via a web-based interface meant for direct, general use. Furthermore, CellMinerCDB is enhanced with new data sources and analyses, including a wide range of fully interoperable pharmacogenomics datasets, as well as multivariate analyses that can be used to explore the biological complexity of these data. The accessibility of these analyses and breadth of available data make CellMinerCDB a unique resource for cancer cell line pharmacogenomic data exploration and hypothesis generation.Figure 1CellMinerCDB Overview(A) CellMinerCDB integrates cancer cell line information from principal resources and provides powerful, user-friendly analysis tools.(B) Summary of molecular and drug activity data for the five data sources currently included in CellMinerCDB. For molecular data types, the numbers indicate the number of genes with a particular data type. GDSC gene-level mutation and methylation data (numbers in red) were prepared from raw data as part of the development of CellMinerCDB. Asterisks indicate molecular data under development, but not publicly available. Protein expression was determined by reverse-phase protein array.(C) Cell line and drug overlaps between data sources.(D) Drug overlaps between data sources.(E) Small cell lung cancer (SCLC) cell line overlaps between data sources.(F) SCLC cell line-tested drug overlaps between data sources.

Here we present CellMinerCDB ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0020}), highlighting key features of molecular and drug data reproducibility, and complementarity across sources. We provide examples illustrating cancer biology explorations and drug response determinants. We propose the potential repurposing of oxyphenisatin acetate (acetalax; NSC59687) as an anticancer agent for triple-negative breast cancer. We demonstrate multivariate analyses for the exploration of genomic response determinants for topoisomerase inhibitors and schweinfurthins, a class of National Cancer Institute (NCI)-developed compounds derived from natural products. CellMinerCDB also provides phenotypic genomic signatures for cancer cell lines, including a gene-expression-based measure of epithelial-to-mesenchymal (EMT) transition status. We demonstrate the use of the latter to assess EMT stratification within specific tissues of origin, leading to the identification of a novel EMT gene, *LIX1L*. Detailed use of CellMinerCDB is described in a video tutorial (<https://youtu.be/XljXazRGkQ8>).

Results {#sec2}
=======

Data Source Comparisons {#sec2.1}
-----------------------

CellMinerCDB integrates four prominent cancer cell line data sources: the CellMiner NCI-60 ([@bib1], [@bib21], [@bib34], [@bib36]), Sanger/Massachusetts General Hospital GDSC ([@bib10]), the Broad/Novartis CCLE, the Broad CTRP ([@bib4], [@bib32]), and a tissue-specific dataset encompassing 66 small cell lung cancer lines (NCI-SCLC) ([@bib30]) ([Figure 1](#fig1){ref-type="fig"}). Collectively, these databases provide drug activity and molecular profiling data for approximately 1,400 distinct cancer cell lines ([Figure 1](#fig1){ref-type="fig"}B, [Supplemental Information](#appsec2){ref-type="sec"}). Each source has particular strengths. The NCI-60 is unmatched with respect to the breadth of molecular profiling data, as well as the number of tested drugs, compounds, and natural products (\>20,000). It also includes replicate data readily accessible via the established CellMiner data portal ([@bib34]). The GDSC, CCLE, and CTRP sources feature much larger numbers of cell lines, spanning tissues of origin not included in the NCI-60. The range of tested compounds in these expanded cell line panels is narrow relative to the NCI-60, although the GDSC and CTRP focus on a wide range of clinically relevant anticancer drugs. The CTRP provides data for 170 US Food and Drug Administration (FDA)-approved or investigational anticancer drugs and 196 other compounds with mechanism of action information. The CTRP molecular data in CellMinerCDB are from the CCLE ([Figure 1](#fig1){ref-type="fig"}B).

Despite ongoing data acquisition and processing efforts, gaps exist with respect to genomic profiling data ([Figure 1](#fig1){ref-type="fig"}B, dark gray table entries). For the GDSC gene mutation and methylation data, we took advantage of processing pipelines developed for the NCI-60 ([@bib35], [@bib36]) to compute gene-level summary data from publicly available raw data. Remaining source-specific molecular profiling data gaps can be filled within CellMinerCDB by effectively extending data provided by one source to another. This is possible because of extensive overlaps between tested cell lines and drugs ([Figure 1](#fig1){ref-type="fig"}). For example, gene-level methylation data are not publicly available for the CCLE, but GDSC methylation data are available for the matching 671 CCLE lines and 597 CTRP lines ([Figure 1](#fig1){ref-type="fig"}C). CellMinerCDB automatically matches synonymous cell line and drug names ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0030}), freeing users from a mundane but time-consuming impediment to work across data sources.

Molecular Data Reproducibility {#sec2.2}
------------------------------

Integrative analyses presuppose data concordance across sources. Such analyses can be readily performed with CellMinerCDB because of the extensive overlaps across the cancer cell line databases: 55 of the NCI-60 lines are in GDSC and 44 are in CCLE, 671 lines (∼60%) are shared between CCLE and GDSC ([Figure 1](#fig1){ref-type="fig"}C), 40 of the 67 NCI-SCLC lines are in GDSC and 36 are in CCLE ([Figure 1](#fig1){ref-type="fig"}E), 74 drugs are in both GDSC and CTRP, and 63 drugs are in both NCI-60 and CTRP ([Figure 1](#fig1){ref-type="fig"}D).

For the genomic data, we assessed concordance by computing Pearson\'s correlations between gene-specific molecular profiles over matched cell lines for all pairs of sources and comparable data types. The distributions of expression, copy number, and methylation data correlations indicate highly significant concordance across sources ([Figure 2](#fig2){ref-type="fig"}A). Concordance was also evident based on non-parametric Spearman\'s rank correlations ([Figure S1](#mmc1){ref-type="supplementary-material"}, related to [Figure 2](#fig2){ref-type="fig"}A). For these analyses, gene-level transcript expression and methylation patterns with uniformly low values across matched cell lines were excluded due to their lack of meaningful pattern ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). The median correlations exceed 0.7 in all cases ([Figure 2](#fig2){ref-type="fig"}A). The striking concordance between NCI-60 and GDSC methylation data (median R = 0.97, median n = 52) may derive in part from the use of same technology platform ([@bib36]) and gene-level data summarization approach ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). Examples for specific genes are displayed in [Figure S2](#mmc1){ref-type="supplementary-material"} (related to [Figure 2](#fig2){ref-type="fig"}A), demonstrating the high data reproducibility for *SLFN11* (Schlafen 11) expression in the NCI-60 versus GDSC, *CDH1* (E-cadherin) expression in GDSC versus CCLE, *SLFN11* methylation in the GDSC versus NCI-60, and *CDKN2A* (p16^INK4^/p19^ARF^) copy number in NCI-60 versus CCLE. Readers are invited to explore their own queries at [https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0035} by selecting a genomic feature for any given gene in two different datasets of their choice.Figure 2Molecular Data Reproducibility across SourcesComparison of the available genomic features of the cell lines shared between the CellMinerCDB data sources. Bar plots indicate the median and inter-quartile range.(A) Pearson\'s correlation distributions for comparable expression (exp), DNA copy number (cop), and DNA methylation (met) data.(B) Jaccard coefficient distributions for comparable binary mutation (mut) data. The Jaccard coefficient for a pair of gene-specific mutation profiles is the ratio of the number of mutated cell lines reported by both sources to the number of mutated lines reported by either source.(C and D) Overlaps of function-impacting mutations as predicted using SIFT/PolyPhen2 for selected tumor suppressor genes and oncogenes. Matched cell line mutation data were binarized by assigning a value of 1 to lines with a homozygous mutation probability greater than a threshold, which was set to 0.3 for (B) and for oncogenes in (C) and to 0.7 for tumor suppressor genes in (D).

Gene-level mutation values in CellMinerCDB indicate the probability that an observed mutation is homozygous and is function impacting. For genes with multiple deleterious mutations in a given cell line, values are converted to cumulative probability values ([@bib35]), and are available in graphical and tabular forms at [https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0040}. To compare mutation profiles across sources, we binarized the matched cell line data by assigning a value of 1 to lines with an aforementioned probability value greater than 0.3. This value was selected to be below the formally expected value of 0.5 for a heterozygous mutation to allow for technical variability.

Entirely matched mutation profiles across sources should have a Jaccard index value of 1. As such, the similarity index distributions indicate greater discordance for the mutation data ([Figure 2](#fig2){ref-type="fig"}B) than for the other types of genomic data ([Figure 2](#fig2){ref-type="fig"}A). The similarity distribution values are higher for the NCI-60 (NCI-60/GDSC median J = 0.5, n = 55; NCI-60/CCLE median J = 0.71, n = 39) than for the GDSC/CCLE comparison (median J = 0.38, n = 593). One caveat, however, is that the large cell line database comparisons entail far larger numbers of matched cell lines. Indeed, the Jaccard similarity values approaching 1 with the NCI-60 comparisons often derive from just one or two matched mutant cell lines. We used similar processing steps to derive gene-level mutation data from variant call data for the NCI-60, GDSC, and CCLE ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). Still, inconsistencies were notable.

Differences between the underlying sequencing technologies and initial data preparation methods are likely to account for the observed discrepancies between the gene mutation data across the datasets. For example, the CCLE mutation data were obtained for a selected set of 1,667 cancer-associated genes subject to high-depth exome capture sequencing ([@bib4]). They consistently yielded the largest numbers of cell lines with function-impacting mutations. The greater number of mutations found for *KRAS*, *PTEN*, *BRAF*, *NRAS,* or *MSH6* in CCLE relative to the GDSC or NCI-60 databases (evaluated by global exome sequencing; [Figure S3](#mmc1){ref-type="supplementary-material"}, related to [Figures 2](#fig2){ref-type="fig"}C and 2D) reflects the importance of sequencing depth for accurate assessment of mutations.

For a more focused and translational assessment of mutation data concordance, we examined the overlap between sources for established oncogenes and tumor suppressor genes ([Figures 2](#fig2){ref-type="fig"}C and 2D, [Table S1](#mmc2){ref-type="supplementary-material"}). For the tumor suppressors, we binarized the data using a probability threshold of 0.7 (to account for the recessive nature of such mutations), whereas for the oncogenes, a 0.3 threshold was used (to account for the dominance of oncogene-activating mutations). These values were set below the formally expected values of 1 and 0.5 for homozygous and heterozygous mutations, respectively, to allow for technical variability. As expected, the most frequently mutated genes were TP53, KRAS, BRAF, APC, RB1, NF1, PTEN, SMARCA4, and MLH1 ([Table S1](#mmc2){ref-type="supplementary-material"}, related to [Figure 2](#fig2){ref-type="fig"}). BRAF mutation profiles showed the expected overlap (J \> 0.7) across datasets, as was the case for the TP53 gene across the GDSC and CCLE (J = 0.69). On the other hand, PIK3CA, BRCA2, BRCA1, MLH1, MSH6, and MSH2 mutation comparisons were largely divergent. These discrepancies reflect the ongoing challenges and trade-offs with mutation profiling technologies and mutation calling procedures. The ability of CellMinerCDB to compare and integrate data across sources highlights the fundamental research efforts and technological standards still required for the accurate identification of mutations. As a practical matter, CellMinerCDB users can readily compare cell line mutation calls across sources for any given gene of interest. For follow-up studies, they can then select either cell lines that are consistently identified as mutant across sources or the larger set of mutant lines (according to one or more sources).

Drug Activity Data Reproducibility and Enrichment {#sec2.3}
-------------------------------------------------

Independent studies have examined drug data reproducibility, noting potential sources of data divergence such as assay type and duration of drug treatments ([@bib8], [@bib11], [@bib13]). To explore the reproducibility and the ability of CellMinerCDB to identify genomic signatures over a larger number of cell lines from different tissues of origin, we tested a selected set of NCI-60-screened compounds in the larger GDSC panel ([Table S2](#mmc3){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}). Noting that the GDSC and the NCI/Developmental Therapeutics Program (DTP) used different assays to determine their IC50 values (Cell Titer Glo measurements of ATP at 72 hr post-treatment versus sulforhodamine B measurement of total protein at 48 hr post-treatment, with additional differences in cell seeding densities and drug dose ranges), we tested in parallel 19 drugs referenced by their NSCs (National Service Center identifiers) and associated with a range of mechanisms of action.Figure 3Drug Activity Data Reproducibility(A and B) GDSC versus NCI-60 drug activity data in matched cell lines for (A) oxyphenisatin acetate (acetalax; NSC59687) and (B) MJ-III-65 (LMP744; NSC706744). Each point represents a matched cell line. Red points in (A) indicate triple-negative breast cancer cell lines.(C--H) (C and D) A total of 38 drugs were tested in the NCI-60, GDSC, and CTRP. CCLE was excluded because of its small drug dataset (24 drugs), which is largely included in CTRP. For each of the three inter-source comparisons, drugs were ranked by activity correlation strength (q-value), with ranks scaled between 0 (lowest) and 1 (highest). Specifically active compounds, such as the BRAF inhibitor dabrafenib, show strong correlations based on the response of melanoma lines shown in red (E and F), whereas broadly active compounds, such as the topoisomerase I inhibitor topotecan, show strong correlations based on broad response patterns (G and H). The NCI-60-matched data in (F) and (H) capture the pattern observed with matched data between the larger GDSC and CTRP collections. The full data table excerpted in (D) is shown in [Figure S6](#mmc1){ref-type="supplementary-material"}.

Two drugs with the strongest correlations were oxyphenisatin acetate (acetalax) and bisacodyl ([Figure 3](#fig3){ref-type="fig"}A, R = 0.84, p = 8.6 × 10^−13^, N = 44 and R = 0.80, N = 43, p = 1.0 × 10^−10^, respectively). These FDA-approved laxatives were included in our comparative analysis based on their range of antiproliferative activity in the NCI-60 (further corroborated by NCI-60 activity data for several derivatives), unique pattern of activity compared with the FDA-approved anticancer drugs, outstanding activity in two of the three NCI-60 triple-negative breast cancer cell lines, and lack of pre-existing data in the CTRP, CCLE, or GDSC. The GDSC results confirmed that oxyphenisatin acetate (acetalax) elicits a broad range of cytotoxic responses in the expanded GDSC cell line collection. Extending our NCI-60 observations, it is more active than any of the 15 tested oncologic drugs by a significant margin (p \< 7 × 10^−10^) in the 22 GDSC triple-negative breast cancer lines ([Table S3](#mmc4){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}).

Overall, 16 of the 19 newly tested compounds across the NCI-60 and GDSC gave significant correlations ([Table S2](#mmc3){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}). Technical discrepancies were evident for three drugs. Dacarbazine, an alkylating agent related to temozolomide, and vincristine, an anti-tubulin, both had poor reproducibility even within DTP assay replicates. Fulvestrant appeared to be out of the proper concentration range in the DTP assay ([Figure S4](#mmc1){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}). The non-camptothecin indenoisoquinoline-based topoisomerase I inhibitor in clinical trial, LMP744 (NSC 706744; MJ-III-65) ([@bib7]), was also included in our 19-compound test set to assess the similarity of its activity profile with that of topotecan over a larger cell line collection and to enrich the genomic signature associated with its activity (see section [Exploring Drug Response Determinants](#sec2.5){ref-type="sec"}). Consistent with its activity as a topoisomerase I inhibitor ([@bib2], [@bib7]), LMP744 is highly correlated with topotecan in the GDSC testing (R = 0.83, p = 4.2 × 10^−187^, N = 715) ([Figure S5](#mmc1){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}), and exhibits significant activity data concordance between NCI-60 and GDSC (R = 0.66, p = 9.8 × 10^−7^, N = 44) ([Figure 3](#fig3){ref-type="fig"}B).

Further focusing on drug activity data reproducibility, we analyzed the 38 drugs previously tested in each of the three databases with larger numbers of tested drugs (NCI-60, GDSC, and CTRP) ([Figure 3](#fig3){ref-type="fig"}C). For each of the three inter-source comparisons, drugs were ranked by activity correlation strength (q-value, scaled between 0 \[lowest\] and 1 \[highest\]). The drugs were then ordered by the average of the three inter-source comparison rank scores ([Figures 3](#fig3){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}). As noted in earlier studies of drug activity data reproducibility ([@bib13]), strong activity correlations were observed for *specifically active* compounds ([Figures 3](#fig3){ref-type="fig"}E and 3F), such as the BRAF inhibitor dabrafenib, wherein outstanding response occurs in cell lines with the activated kinase target. Notably, we also observed high correlations for *broadly active* drugs, such as the topoisomerase I inhibitor topotecan ([Figures 3](#fig3){ref-type="fig"}G and 3H), indicating that the cancer cell line responses are reproducible across databases and assays and are not limited to protein kinase inhibitors. Still, for many of the 38 assessed drugs (see lower half of [Figure S6](#mmc1){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}), there were discordant activity data between one or more pairs of sources. The inter-source activity data comparisons enabled by CellMinerCDB allow individual researchers to identify drugs with concordant data, so they can pursue reliable molecular pharmacology and translational genomic analyses (see below and [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}).

Exploring Gene Regulatory Determinants {#sec2.4}
--------------------------------------

Cancer-specific gene expression is known to be affected by DNA copy number variations (CNVs) and epigenetic alterations such as promoter methylation. CellMinerCDB makes it easy to explore these and other potential gene regulatory determinants. For example, in the NCI-60, reduced expression of the tumor suppressor gene *CDKN2A* (p16^INK4a^) is associated with both DNA copy loss ([Figure 4](#fig4){ref-type="fig"}A) and promoter hypermethylation ([Figure 4](#fig4){ref-type="fig"}B) across tissue types. Notably, [Figure 4](#fig4){ref-type="fig"}C shows that approximately 25% of NCI-60 cell lines show both alterations, consistent with biallelic, "two-hit" suppression of *CDKN2A* expression. Integration of matched cell line GDSC methylation and CCLE copy number data illustrates the same *CDKN2A* regulatory relationships in a larger cell line collection ([Figures 4](#fig4){ref-type="fig"}D--4F). [Table S4](#mmc5){ref-type="supplementary-material"} (related to [Figure 4](#fig4){ref-type="fig"}) shows that *CDKN2A* stands out with respect to the high proportion of cell lines showing co-occurrence of promoter methylation and DNA copy loss. Conversely, the impact of copy gain on increased oncogene expression can be similarly assessed with CellMinerCDB. [Figure 4](#fig4){ref-type="fig"}G shows that a subset of *MYC*-driven CCLE small cell lung cancer lines (red dots) exhibits both *MYC* copy gain and increased *MYC* gene expression. KRAS activation, typically regarded as mutation driven, can also occur by copy gain, as evident in a subset of CCLE lines ([Figure 4](#fig4){ref-type="fig"}H), consistent with clinical studies ([@bib42]).Figure 4Exploring Gene Expression DeterminantsReduced mRNA expression (xai, average log2 intensity) of the cell cycle inhibitor and tumor suppressor CDKN2A (p16) is associated with DNA copy loss (cop) (A) and promoter methylation (met) (B) in the NCI-60 lines. In a subset of NCI-60 lines, enclosed in the red box, (C), DNA copy loss accompanies higher levels of promoter methylation. DNA copy number and promoter methylation data from the CCLE and GDSC, respectively, can be also be visualized over matched cell lines to verify a similar pattern in larger cell line collections (D--F). Note that the corroboration of the NCI-60 regulatory relationships in a far larger and more diverse cell line set is uniquely enabled by CellMinerCDB, which allows gene-level methylation data only available in the GDSC to complement gene-level DNA copy number data only available in the CCLE (for automatically matched cell lines). DNA copy number gain is associated with increased expression (exp, *Z* score microarray log2 intensity data) of the oncogenes MYC (G) and KRAS (H) in selected CCLE cell lines. In (G), small cell lung cancer lines are indicated in red to highlight a subset potentially derived from MYC-driven tumors (within red box).

Exploring Drug Response Determinants {#sec2.5}
------------------------------------

CellMinerCDB allows correlation analyses and scatterplots for testing and visualizing potential response-determinant relationships (univariate analyses) as well as multivariate linear regression methods for integrating multiple determinants (multivariate analyses; see [Figures 5](#fig5){ref-type="fig"}D and [6](#fig6){ref-type="fig"}B). CellMinerCDB also enables the discovery of candidate genomic determinants of drug response as well as drug-drug correlations ("Compare Pattern" tab in the "Univariate analyses" tool; [https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0045}). This method led to the discovery of Schlafen 11 (*SLFN11*) expression as a causal determinant of response to widely used DNA-targeted anticancer agents, including topoisomerase inhibitors, platinum derivatives, PARP inhibitors, and antimetabolites ([@bib4], [@bib26], [@bib27], [@bib44]). Starting with target expression profiles, CellMinerCDB correlation analyses can identify compounds with matching activity profiles. For example, CellMinerCDB can be used to demonstrate that epidermal growth factor receptor (EGFR) expression is significantly correlated with the activity of erlotinib and afatinib in all major cell line databases, as well as with the activity of other established EGFR inhibitors available in one or more data sources. CellMinerCDB correlation analyses also allow direct evaluation of drug resistance determinants. For example, potential substrates of drug efflux ABC transporters can be recovered because strong negative activity correlates with the expression of ABC drug transporters, as in the case of paclitaxel and ABCB1 in the GDSC (r = −0.33; p value = 5.7 × 10^−12^).Figure 5Exploring Drug Response Determinants(A and B) Response to the pre-mRNA splicing inhibitor indisulam versus expression of its target complex component DCAF15 in the CTRP. Drug response in (B) is measured by the activity area above the dose-response curve, with higher values indicating relative drug sensitivity. A report of increased indisulam sensitivity in hematopoietic cell lines (shown in red) with high DCAF15 expression is readily verified ([@bib12]).(C) Response to the aurora kinase inhibitor alisertib is associated with increased MYC expression in small cell lung cancer lines ([@bib24]).(D) Heatmap indicating etoposide drug activity and candidate determinant gene expression in the 100 most sensitive and resistant CTRP cell lines.(E) Scatterplots of etoposide activity versus candidate determinant gene expression in CTRP cell lines, with hematopoietic cell lines shown in red.(F) A statistical summary of a multivariate linear model of etoposide response in the CTRP.(G) A mechanistic scheme indicating how the selected determinants may influence etoposide drug response.Figure 6A Multivariate Model of Schweinfurthin A Drug Activity(A) Reproducibility of the data for the two schweinfurthin derivatives tested in the GDSC.(B) Heatmap indicating Schweinfurthin A drug activity and candidate determinant gene expression in the 100 most sensitive and resistant non-hematopoietic GDSC cell lines.(C) A statistical summary of a multivariate linear model of Schweinfurthin A response in the GDSC.(D) Scheme of the proposed molecular pharmacology of the schweinfurthins. Schweinfurthins have been shown to inhibit PI3K/AKT signaling and cell survival by binding oxysterol-binding-protein-related proteins (ORPs) to disrupt *trans*-Golgi network trafficking required for robust pathway activity ([@bib3]). Together with the ORPs OSBP, OSBPL3, and OSBPL10, the other candidate determinants, PLEKHO1 and THEM4, have also been implicated in PI3K/AKT signaling ([@bib20], [@bib40]).Plots and analyses in panels B--D are based on non-hematopoietic GDSC cell lines.

CellMinerCDB also allows users to assess on the spot the generality of results presented in the literature, and iteratively explore evidence for multifactorial mechanistic models. [Figure 5](#fig5){ref-type="fig"}A shows an example for indisulam, which targets the splicing factor RBM39 for proteasomal degradation by forming a ternary complex with RBM39 and the E3 ubiquitin ligase receptor DCAF15. A report of increased indisulam sensitivity in hematopoietic cell lines with high *DCAF15* expression is readily verified with CellMinerCDB ([Figure 5](#fig5){ref-type="fig"}B, red dots) ([@bib12]). CellMinerCDB also corroborates a report of *MYC*-driven small cell lung cancer exhibiting vulnerability to aurora kinase inhibition ([@bib24]) ([Figure 5](#fig5){ref-type="fig"}C).

As determinants of drug responses are multifactorial, CellMinerCDB includes a multivariate analysis tool under the "Regression Models" tab. [Figures 5](#fig5){ref-type="fig"}D--5G illustrate its use for the topoisomerase II inhibitor etoposide. Starting with expression of the drug target (*TOP2A* and *TOP2B*) ([@bib31]) and *SLFN11* ([@bib44]), users can select additional determinants based on biological knowledge. Determinant selection can be further guided by pathway annotations, as well as partial correlation analyses, which measure the capacity of additional features to improve the current model ([Figure 5](#fig5){ref-type="fig"}G). Additional determinants can be found using the "LASSO" tool in the "Algorithm" dropdown menu of the "Regression Models" tab of the CellMinerCDB website. The use of the multivariate modeling tools included in the "Regression Models" tab is outlined in the video tutorial (<https://youtu.be/XljXazRGkQ8>) and will be exemplified below in the A Multivariate Model of Schweinfurthin A Drug Activity section.

Benefits of Analyses over Multiple Data Sources {#sec2.6}
-----------------------------------------------

The uniform data representation, accessibility, and interoperability provided by CellMinerCDB allows direct exploratory analyses across the datasets (NCI-60, CCLE, GDSC, CTRP, NCI/DTP-SCLC). This is critically important to identify molecular and drug response determinants with consistent data across sources for specific analyses. The automatic management of cell line overlaps also enables comprehensive analyses encompassing all databases, using complementary data to supplement source-associated gaps in molecular and drug activity data (see [Figure 1](#fig1){ref-type="fig"}, and prior section). These application features are highlighted in the examples presented below.

The main ABC transporter, ABCB1 (PgP), is a dominant factor conferring resistance to multiple classes of clinically relevant drugs. Because CellMinerCDB integrates different databases with different drugs tested in each database, it can reliably test the relationship between drug resistance and ABCB1 expression. The first step ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0055}) is to ensure that ABCB1 expression exhibits a high dynamic range (i.e., cells with and without expression and high expression in the positive cells) and that ABCB1 expression is highly correlated across databases. [Figure S7](#mmc1){ref-type="supplementary-material"}A (expression of ABCB1 across GDSC and CCLE) shows very high correlation between the two databases (r = 0.91; p value = 1.4 × 10^−238^). The next step is to use the "Compare Patterns" tool of CellMinerCDB by entering "ABCB1" as the "x-Axis Data Type" for each of the databases (selected via the "x-Axis Cell Line Set"). [Table S5](#mmc6){ref-type="supplementary-material"} (related to [Figure 5](#fig5){ref-type="fig"}) shows the top 50 drugs with activity negatively correlated with ABCB1 for the three datasets: GDSC, CTRP (CCLE), and NCI-60. Overlapping and established drugs effluxed by ABCB1 in each dataset are highlighted in yellow. In addition, each dataset includes many additional drugs. Therefore, if a drug is not in one dataset, it may be found in others. [Figure S8](#mmc1){ref-type="supplementary-material"} (related to [Figure 5](#fig5){ref-type="fig"}) shows that adding ABCB1 to SLFN11 enhances the prediction of doxorubicin activity. This analysis is readily done using the "Regression Models" tool of CellMinerCDB. Finally, [Figure S7](#mmc1){ref-type="supplementary-material"} (related to [Figure 4](#fig4){ref-type="fig"}) shows that ABCB1 is epigenetically regulated by promoter hypermethylation [Figure S7](#mmc1){ref-type="supplementary-material"}B rather than by copy number alteration [Figure S7](#mmc1){ref-type="supplementary-material"}C.

[Figure S9](#mmc1){ref-type="supplementary-material"} (related to [Figure 5](#fig5){ref-type="fig"}) presents an example of cross-database exploration to identify cyclin D1 (CCND1) as a potential determinant of response to the HDAC inhibitor belinostat, together with evidence of CCND1 expression regulation by DNA copy number and promoter methylation.

A Multivariate Model of Schweinfurthin A Drug Activity {#sec2.7}
------------------------------------------------------

Schweinfurthin A was discovered by the NCI natural products initiative ([@bib38]) to identify compounds with distinctive NCI-60 activity profiles indicative of novel targets (via COMPARE analysis; [@bib29]). Its wide activity range with notable potency in leukemia and CNS lines (\<10 nmol/L) motivated the synthesis of a series of derivatives ([@bib16]). Because the development of schweinfuthins has been hampered by limited understanding of their molecular pharmacology, we tested Schweinfurthin A and 5'-methylschweinfurthin G (NSC 746620) in the GDSC panel and applied the various features of CellMinerCDB to reveal the molecular pathways for response. After confirming that the activities of both compounds were highly correlated (R = 0.87, p = 8.8 × 10^−182^, N = 585, [Figure 6](#fig6){ref-type="fig"}A), we explored the genomic correlates with activity for the ≈700 GDSC cell lines tested. The CellMinerCDB Univariate Analysis tool ("Compare Patterns" tab) indicates that the leading molecular correlate (by lowest p value) of schweinfurthin activity is the expression of *PLEKHO1*, a negative regulator of phosphatidylinositol 3-kinase (PI3K)/AKT signaling (R = 0.47, p = 1.95 × 10^−33^, N = 582) ([@bib40]). This result is consistent with a recent study showing that schweinfurthins inhibit mammalian target of rapamycin (mTOR)/AKT signaling by interfering with *trans*-Golgi network (TGN) trafficking ([@bib3]). In particular, schweinfurthins bind to oxysterol-binding proteins, which regulate TGN trafficking ([@bib6], [@bib23]), thereby arresting lipid-raft-mediated PI3K activation and functional mTOR/RheB complex formation.

Next, using the multivariate analysis feature of CellMinerCDB ("Regression Models" tab; [https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0060}), we developed a linear predictive model for schweinfurthin response integrating the expressions of *PLEKHO1*, *THEM4*, a positive regulator of AKT signaling ([@bib20]), and the genes encoding the oxysterol-binding protein family members *OSBP*, *OSBPL3*, and *OSBP10* ([Figures 6](#fig6){ref-type="fig"}C and 6D). Increased expression of the oxysterol-binding protein family members conceivably sustains TGN trafficking and PI3K/AKT signaling, in keeping with their negative regression coefficient weights as resistance determinants in the model. The negative weighting of *THEM4* expression and positive weighting of *PLEKHO1* expression are similarly consistent with their respective roles in activating and suppressing PI3K/AKT signaling. These analyses give molecular insight into the cholesterol trafficking and intracellular membrane pathways as the targets of schweinfurthins and open new opportunities for testing the potential activity of schweinfurthins with genomic and molecular signatures.

Relating EMT Status with Gene Expression to Identify *LIX1L* Expression and Schweinfurthin Activity in Mesenchymal Cells {#sec2.8}
------------------------------------------------------------------------------------------------------------------------

EMT is a fundamental process in development, wound healing, and cancer progression, characterized by the loss of cell-cell adhesion and the acquisition of motile and invasive properties ([Figure 7](#fig7){ref-type="fig"}A) ([@bib15], [@bib18]). EMT is driven by dominant transcription factors, including ZEB1/2, SNAI1/2, and TWIST1/2, and is reversible through a continuum of states from epithelial to mesenchymal. These attributes have motivated the development of gene-expression-based EMT signatures to identify cell line state and understand drug resistance.Figure 7Relating Epithelial Mesenchymal Transition (EMT) Status with Gene Expression to Identify *LIX1L* as a Novel EMT Gene(A) A 37-gene EMT signature developed in ([@bib17]) was used to derive a numerical index of EMT status as a weighted sum of cell-line-specific EMT gene expression values (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} for details). Epithelial and mesenchymal statuses are associated with positive and negative index values, respectively.(B) For 821 non-hematopoietic cell lines in the GDSC collection, the EMT index values show a bimodal distribution, which can be modeled as a normal mixture. Cell lines with EMT index values less than (greater than) 1 standard deviation above (below) the putative mesenchymal (epithelial) group mean are annotated as mesenchymal (epithelial).(C) EMT stratification by tissue of origin.(D and E) Expression of *LIX1L*, a novel mesenchymal gene, is strongly correlated with the EMT index signature. "Epithelial-mesenchymal" lines with intermediate EMT index values are indicated in red. Mesenchymal lines are in blue at the left, and epithelial are in blue at the right.(F) Western blot showing the efficient knockdown of LIX1L in MDA-MB231 cells.(G) Representative image showing increased migration and invasion after LIX1L knockdown.(H) Quantitation of the increased migration and invasion of cells after LIX1L knockdown. Individual experiments are shown as dots. Error bars indicate the standard error of the mean.

We applied a 37-gene EMT signature initially developed in the NCI-60 ([@bib17]) to derive a numerical index of EMT status as a weighted sum of cell-line-specific EMT expression values ([Transparent Methods](#mmc1){ref-type="supplementary-material"}). [Figure 7](#fig7){ref-type="fig"}B shows the bimodal distribution for the EMT index values across the 821 non-hematopoietic GDSC cell lines, allowing cell line stratification into epithelial, mesenchymal, and epithelial-mesenchymal categories. EMT stratification within particular tissues of origin also shows a substantial proportion of intermediate epithelial-mesenchymal lines in liver, ovary, and lung cancer cell lines ([Figure 7](#fig7){ref-type="fig"}C). The numerical EMT index is available for all CellMinerCDB-integrated data sources as the variable KOHN_EMT_PC1 ("Metadata"), allowing its correlation with any chosen molecular or drug response feature.

The EMT index identified *LIX1L* as a novel mesenchymal gene whose expression is highly correlated with the EMT index signature ([@bib17]) across multiple cancer types ([Figure 7](#fig7){ref-type="fig"}D, R = −0.75, p = 8.9 × 10^−179^, N = 823). *LIX1L* is also broadly expressed in TCGA tumor samples ([Figure S10](#mmc1){ref-type="supplementary-material"}A, related to [Figure 7](#fig7){ref-type="fig"}). Knockdown analyses in the breast cancer MDA-MB-231 cell line suggest that *LIX1L* expression reduces cell migration and invasiveness ([Figures 7](#fig7){ref-type="fig"}F--7H, [S10](#mmc1){ref-type="supplementary-material"}C, and S10D).

We also correlated the EMT index with the activity profiles of the 297 compounds in the GDSC database, including the 19 additional compounds tested for the current study ([Figure S11](#mmc1){ref-type="supplementary-material"}, related to [Figure 7](#fig7){ref-type="fig"}). Schweinfurthin A is the strongest negative correlate, indicating its selective antiproliferative activity in mesenchymal cancer cell lines, such as those derived from bone or soft tissue ([Figure S11](#mmc1){ref-type="supplementary-material"}C). The second strongest negative correlate with the EMT index is the RHO-associated kinase 1 inhibitor GSK269962A ([Figure S11](#mmc1){ref-type="supplementary-material"}C), whose target regulates actin dynamics and cell motility associated with EMT ([@bib15], [@bib18]). On the opposite side, the drug most highly correlated with epithelial cell line status was acetalax (oxyphenisatin), with its two independent samples (NSC59687 and 614826) at the top of the list above afatinib and lapatinib ([Figure S11](#mmc1){ref-type="supplementary-material"}C), consistent with its potential activity in epithelial breast cancer cells ([@bib25]).

Discussion {#sec3}
==========

CellMinerCDB ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0065}) allows researchers to interact directly with an unparalleled breadth of cancer cell line genomic and pharmacologic data. The examples described here, spanning data assessment, integration, and discovery, demonstrate the value of working within and across data sources.

The CellMinerCDB analyses support the maturity and essential reproducibility of most molecular profiling technology platforms, such as gene transcript expression and DNA CNV. Mutation data are prominently featured in translational studies, and CellMinerCDB exposes the issue of discrepancies between matched cell line mutation profiles across sources. This provides a foundation for understanding and mitigating sources of variability, which reflect the ongoing technical challenges and trade-offs with the acquisition and interpretation of genome sequencing data. Somatic variant calling in cancer cell lines is inherently challenging because of the absence of matched normal tissue for comparison, as well as the potentially higher mutation burden in cell lines relative to primary tumor tissue. One approach for excluding potentially cell-line-specific passenger mutations is to filter variants based on frequency in patient populations ([@bib14]). Variability in cell line mutation data across sources may also arise from differences in variant calling algorithms, as well as data sources used for filtering likely germline variants. Indeed, the reproducibility of matched cell line gene expression, DNA copy number, and methylation signatures across databases (see [Figures 2](#fig2){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}, and [S2](#mmc1){ref-type="supplementary-material"}) indicates that the mutation data inconsistencies are likely technical. An existing strategy for acquiring more robust mutation data is to pursue higher-depth targeted sequencing of a restricted gene set. Indeed, we noted that the CCLE data, derived from the latter approach, consistently identified more mutant cell lines for prominent oncogenes and tumor suppressor genes than genome-wide exome sequencing (as in the NCI-60 and GDSC databases). CellMinerCDB can directly integrate mutation data across sources to identify cell lines with consistent mutation calls for a gene of interest, together with other potentially impacted lines. Given the primarily technical basis for the mutation data discrepancies, the best course for users remains this sort of comparison of data across sources. CellMinerCDB enables researchers to focus on consistently mutation-impacted cell lines for further bioinformatic analyses and experimental use (including targeted high-depth sequencing for specific genes of interest).

Regarding drug reproducibility, assays across the major cancer cell line data sources measure different biochemical features at different time points. Still, CellMinerCDB demonstrates significant concordance between drug activity data generated at the NCI (NCI-60 and NCI/DTP-SCLC), at the Broad Institute (CCLE, CTRP), and at the Sanger Institute and Massachusetts General Hospital (GDSC), including data for widely used anticancer drugs. The cross-database comparison features of CellMinerCDB allow researchers to explore potential drug reproducibility issues and focus on drugs with reliable data. Scatterplots of matched cell line activity data can highlight problem areas with particular assays, such as inappropriate concentration ranges, as illustrated for fulvestrant in the NCI/DTP assay.

In addition, among the 19 NCI-60 drugs tested for reproducibility and expansion of genomic correlates, we found significant consistency for 16 drugs, including the novel non-camptothecin topoisomerase I inhibitor LMP744 ([@bib7]), and identified the FDA-approved laxatives oxyphenisatin acetate (acetalax) and bisacodyl as potential novel anticancer drug candidates. CellMinerCDB shows ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0070}) that oxyphenisatin exhibits a wide range of concordant antiproliferative activity across the NCI-60 cell lines and across the 710 GDSC cell lines tested, being substantially more active in triple-negative breast cancer lines relative to other cancer drugs tested on the GDSC panel. These findings suggest the potential of oxyphenisatin derivatives for repurposing as anticancer drugs.

With both drug activity reproducibility and broader associations between molecular features, such as *CDKN2A* expression and gene copy/methylation, we noted that the NCI-60 could effectively capture relationships evident in larger cell line sets. The latter better reflect tissue type diversity and context-specific molecular features. Still, for dominant associations, such as *SLFN11* expression and DNA-targeted drug responses, representative cell line sets such as the NCI-60 are often sufficient ([@bib44]). In addition, the NCI-60 provides drug responses for over 21,000 individual agents, making it an unmatched resource for the discovery of new chemotypes based on correlations with genomic data and response patterns for drugs with known targets. CellMinerCDB makes correlation-based COMPARE analyses readily accessible for drug discovery (<https://dtp.cancer.gov/databases_tools/compare.htm> \[[@bib29]\]). It also enables a direct visualization of activity data for compounds retrieved in the analysis together with data for the queried entity, using the "Univariate Analysis" tool ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0080}). The NCI databases are also a tractable starting point for molecular data expansion with leading-edge technologies. RNA sequencing data with isoform-specific transcript expression and SWATH mass spectrometry-based protein expression data have been generated for the NCI-60, and will be made available within CellMinerCDB ([@bib37]). We are committed to sustain development of CellMinerCDB as an ongoing resource in the mold of the existing NCI CellMiner data portal, which has steadily integrated new data and analyses since its inception ([@bib33], [@bib35], [@bib34], [@bib36]). These developments will expand the current features of CellMinerCDB. For example, as existing and emerging data sources provide novel proteomic and isoform-specific transcript expression data, we are planning to integrate these with regular updates of the same website.

CellMinerCDB ([https://discover.nci.nih.gov/cellminercdb/](https://discover.nci.nih.gov/cellminercdb_reviewers/){#intref0085}) ultimately aims to provide a seamless platform for data exploration and hypothesis generation, integrating previously isolated data sources and enhancing their interpretation through the intuition and expertise of experimental scientists and clinicians. The present publication provides only a sample of the potential uses of CellMinerCDB. CellMinerCDB uniquely complements existing data portals that provide detailed information on their associated data, together with specialized analyses. By empowering researchers to easily build on the strengths of individual databases and pursue their own questions, CellMinerCDB aims to advance the potential of cancer cell line pharmacogenomic data to lay the foundation, validate, and focus experimental and, ultimately, clinical drug development and precision medicine.

Limitations of the Study {#sec3.1}
------------------------

We see CellMinerCDB as primarily a data exploration and hypothesis generation tool. Its selection of analyses reflects what is practically manageable in this context, both computationally and conceptually. For example, we do not provide analyses with extended runtimes that are less suitable for interactive data exploration. We do, however, make all data integrated within the application easily downloadable, to expedite more specialized or computationally intensive analyses. CellMinerCDB still provides interactive access to the most fundamental methods, including regression-based predictive models, which have been prominently featured in highly cited studies of cancer cell line pharmacogenomic data.

We have also attempted to minimize the conceptual barrier for basic exploratory analyses by making reasonable default choices for this setting. In keeping with existing CellMiner tools (<http://discover.nci.nih.gov/cellminer>) ([@bib33], [@bib35], [@bib34], [@bib36]) and leading studies, we use Pearson\'s correlations to measure association between molecular or drug response variables. We do note for users that statistical significance results for these correlations presuppose approximately multivariate normal data; substantial deviations from this assumption can be readily noted through the provided scatterplots. Still, a comparative study of CCLE and GDSC data favored Pearson correlations over non-parametric Spearman correlations, showing that the latter often failed to detect patterns in which responses are restricted to a relatively small fraction of cell lines (as will often be the case for pathway-targeted drugs) ([@bib8]).

In keeping with the exploratory focus of CellMinerCDB, we do not enforce formal adjustments for multiple hypothesis testing (although our pattern comparison and related results do include tabulation of q-values to allow false-discovery-rate-based filtering). The strictest adjustment for multiple testing would require inaccessible knowledge of all analyses conducted by a user toward a particular aim. This sort of application of statistical filters would likely exclude many experimentally established relationships that involve more than one determinant.

Our goal is to strike a balance between providing statistical measures (with reasonable caveats), and allowing scientific experts to apply their judgment when exploring data. We finally note that it is possible to consider additional levels of inter-source data integration. For example, pooling molecular or drug data for distinct cell lines across sources (as compared to strictly overlapping cell lines) could increase the power of statistical analyses. This approach, although potentially valuable, would require careful assessment and adjustment for source-specific effects and is outside the scope of the current study.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods and Figures S1--S11Table S1. Oncogene/Tumor Suppressor Gene Mutation Call Frequencies and Inter-source Overlaps, Related to Figure 2Oncogene and tumor suppressor gene mutation call frequencies and overlaps across data sources.Table S2. GDSC versus NCI/DTP Drug Activity Data Comparison, Related to Figure 3Comparison of drug activities as measured by the GDSC and the NCI/DTP.Table S3. Bisacodyl and Acetalax Activity in GDSC Triple-Negative Breast Cancer Lines, Related to Figure 3Activity of bisacodyl and oxyphenisatin acetate (acetalax) in GDSC triple-negative breast cancer lines.Table S4. Co-occurrence of Gene Promoter Methylation and DNA Copy Loss, Related to Figure 4Co-occurrence of gene promoter methylation and DNA copy loss.Table S5. Drugs with Activity Negatively Correlated with ABCB1 Expression, Related to Figure 5Top 50 drugs with respect to negative activity correlation with ABCB1 expression for the GDSC, CTRP (CCLE), and NCI-60 datasets.
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